ABBV Jan 2025 70.000 put
- PR Newswire
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers
AbbVie (NYSE: ABBV) today launched the AbbVie Migraine Career Catalyst AwardTM, a first-of-its-kind contest designed to support the career, workplace, and professional development aspirations of people living with migraine. With more than 113 million workdays lost in the U.S. each year to the disease and its symptoms, migraine can have a major impact in the workplace.1 Twenty contest entrants will win up to $2,500 that they can decide to use toward career support, including career counseling, pr
- PR Newswire
AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383
AbbVie (NYSE: ABBV) today announced that the first patient has been treated with investigational ABBV-383 in the CERVINO Phase 3 study. ABBV-383 is a distinctive B-cell maturation antigen (BCMA) and CD3 bispecific antibody T-cell engager composed of bivalent BCMA-binding domains allowing for high BCMA-avidity and a low-affinity CD3 binding domain.1 ABBV-383 is being evaluated in a Phase 3, multicenter, randomized, open-label study compared with standard available therapies in patients with r/r M
- PR Newswire
RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis
AbbVie (NYSE: ABBV) today announced that RINVOQ® (upadacitinib) is indicated in the U.S. for the treatment of pediatric patients two years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) as well as psoriatic arthritis (PsA), provided they have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. Additionally, a new weight-based oral solution, RINVOQ® LQ (upadacitinib), is now available as an option for these pediatric popu
